Kinship

Kinship (2026)



0.0 2026 — —
Documentary
Journey alongside a veteran globetrotter across diverse landscapes to decode the shifting bond between people and nonhuman species. Guided by culinary evolution, enduring cultural practices, and cutting-edge advancements, this compelling exploration highlights the transition from animal commodification to genuine empathy and interconnected living. Discover how mindful consumption, heritage preservation, and progressive solutions are reshaping our ethical landscape worldwide.

More About This Film

Cardigan, Inc. has announced significant progress in its clinical development pipeline for Danicamtiv, a novel myosin activator designed to treat genetic dilated cardiomyopathy (DCM). The company recently completed enrollment of the first cohort in the Phase 2/3 KINSHIP-DCM adaptive trial, which targets patients with specific genetic mutations including MYH7 and TTN. This milestone marks a critical step toward potentially addressing unmet medical needs in cardiovascular diseases where no approved therapies currently exist.

  • Danicamtiv aims to restore myosin function and availability, directly targeting the underlying sarcomeric defects associated with genetic DCM.
  • The KINSHIP-DCM trial is an adaptive, randomized, placebo-controlled study evaluating both Phase 2b and Phase 3 components.
  • Company executives expect top-line data from the Phase 2b portion of the trial in the first half of 2027.
  • Preclinical and clinical evidence linking Danicamtiv treatment to improved right ventricular function will be presented at the European Society of Cardiology Congress in August 2026.

Where to Watch

This title refers to a clinical trial program and corporate entity rather than a commercial motion picture available for consumer viewing.